High delivery rates for lipid based drug formulations, and methods of treatment thereof
View Patent ↗Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.
1. A method of delivering a liposomal aminoglycoside formulation at a rate of 10 to 25 mg/min of aminoglycoside comprising nebulizing the liposomal aminoglycoside formulation, wherein the liposomal aminoglycoside formulation comprises a lipid bilayer and an aminoglycoside encapsulated therein, and wherein the formulation has a lipid to aminoglycoside (L/D) weight ratio ranging from 0.40:1 to 0.49:1.
2. The method of claim 1 , wherein the amount of aminoglycoside encapsulated in the liposome after the nebulization is greater than 45% of the amount of aminoglycoside encapsulated before the nebulization.
3. The method of claim 1 , wherein the lipid is a mixture of a phospholipid and a sterol.
4. The method of claim 3 , wherein the phospholipid is dipalmitoylphosphatidylcholine (DPPC) and the sterol is cholesterol.
5. The method of claim 4 , wherein the DPPC:cholesterol ratio is 2:1 by weight.
6. The method of claim 1 , wherein the aminoglycoside is amikacin.
7. The method of claim 1 , wherein the aminoglycoside is tobramycin.
8. The method of claim 1 , wherein the aminoglycoside is gentamicin.
9. A method of treating a patient for a pulmonary infection comprising administering to the patient in need thereof a therapeutically effective amount of a liposomal aminoglycoside formulation, wherein the liposomal aminoglycoside formulation comprises a lipid bilayer and an aminoglycoside encapsulated therein, and wherein the formulation has a lipid to aminoglycoside (L/D) weight ratio ranging from 0.40:1 to 0.49:1.
10. The method of claim 9 , wherein the aminoglycoside is amikacin.
11. The method of claim 9 , wherein the aminoglycoside is tobramycin.
12. The method of claim 9 , wherein the aminoglycoside is gentamicin.
13. The method of claim 9 , wherein the pulmonary infection is a pseudomonas, P. aeruginosa, P. paucimobilis, P. putida, P. fluorescens , and P. acidovorans , staphylococcal, Methicillinresistant Staphylococcus aureus (MRSA), streptococcal, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Enterobacter, Serratia, Haemophilus, Yersinia pesos, Burkholderia pseudomallei, B. cepacia, B. gladioli, B. multivorans, B. vietnamiensis, Mycobacterium tuberculosis, M. avium complex (MAC), M. avium, M. intracellulare, M. kansasii, M. xenopi, M. marinum, M. ulcerans, M. fortuitum complex, M. fortuitum , or M. chelonei infection.
14. The method of claim 9 , wherein the patient has cystic fibrosis.
15. The method of claim 10 , wherein the patient has cystic fibrosis.
16. The method of claim 11 , wherein the patient has cystic fibrosis.
17. The method of claim 12 , wherein the patient has cystic fibrosis.
18. The method of claim 1 , using a nebulizer compressor pressure of 20 to 40 psi.